LEADERSHIP

Neil F. McFarlane

Neil F. McFarlane has served as our president, chief executive officer, and a director of our Company since October 2023. Mr. McFarlane served as a member of the board of directors of Collegium Pharmaceutical Inc. between April 2022 and July 2024. Previously, Mr. McFarlane served as the chief executive officer and a member of the board of directors of Adamas Pharmaceuticals, Inc. from September 2019 until its acquisition by Supernus Pharmaceuticals, Inc. in November 2021. Mr. McFarlane worked as an independent consultant between June 2019 and August 2019 and again between December 2021 and September 2023 providing consulting services for biotechnology, pharmaceutical, and financial services companies. From August 2016 to May 2019, Mr. McFarlane served as the chief operating officer of Retrophin, Inc., now known as Travere Therapeutics, Inc., where he was responsible for overseeing operations. From 2011 to 2016 Mr. McFarlane served as vice president and general manager of UCB, Inc.’s U.S. Immunology Business Unit and as vice president for its Global Bone Business Unit in collaboration with Amgen Inc. Prior to his positions at UCB, Mr. McFarlane held positions of increasing responsibility with Genzyme Corporation (“Genzyme”) and Sangstat Medical Corporation prior to its acquisition by Genzyme. Mr. McFarlane previously served as an officer and enlisted soldier in the United States Army Reserves. He received his B.S. degree and M.S. degree in Nursing from the University of Florida. Our Board believes that Mr. McFarlane’s over 20 years of global biopharmaceutical and life sciences experience provide him with the qualifications and skills to serve as a director.

Joshua Schafer

Joshua Schafer has served as Zevra’s Chief Commercial Officer since January 2023. From January 2023 to March 2025, in addition to serving as our Chief Commercial Officer, he served as our Executive Vice President, Business Development. Mr. Schafer brings to Zevra over 25 years of pharmaceutical commercial, new product development and merger and acquisition (M&A) experience.

Mr. Schafer previously served as General Manager of the Autoimmune and Rare Disease business at Mallinckrodt Pharmaceuticals, and prior to that, he served as Chief Strategy and Business Officer. During his professional career, he has successfully led over $16 billion in aggregate M&A transactions. Prior to Mallinckrodt, Mr. Schafer served as Vice President and Oncology Therapeutic Area Head, Global Marketing and Strategy at Astellas Pharmaceuticals, where he was responsible for building the company’s global oncology franchise, and also held senior roles at Takeda Pharmaceuticals, Accenture (formerly Anderson Consulting), G. D. Searle & Co. (later acquired by Pfizer) and Cognia Corporation. Mr. Schafer currently serves as a Board member of Pharnext SA and Shuttle Pharmaceuticals. He received his B.A. in Biology and German at the University of Notre Dame, and both an M.S. in Biotechnology and an M.B.A. from Northwestern University.

Adrian Quartel, M.D., FFPM

Dr. Quartel was previously the Chief Medical Officer of Acer Therapeutics, where he played a key role in guiding clinical development, medical affairs and regulatory compliance. Zevra recently acquired Acer Therapeutics and his significant contributions there incorporating multiple rare disease assets into its portfolio gained prominence. Prior to that, he was the Chief Medical Officer at Adamas Pharmaceuticals, a company focused on drug development for neurological diseases. He previously served as the former Group Vice President of Global Medical Affairs at BioMarin Pharmaceuticals Inc., where he spearheaded the launch of six treatments for rare diseases or genetic disorders, including KUVAN®, VIMIZIM®, and Brineura®. Before his tenure at BioMarin, he oversaw clinical development and held senior medical leadership positions at Astellas, Chiltern, and ICON Clinical Research. Earlier in his career, Dr. Quartel worked as a clinical research fellow at UCLA Cedar Sinai and as a resident in cardio-thoracic surgery at Erasmus University Medical Center. He holds an M.D. from Erasmus University Medical School, Rotterdam, and has a postgraduate specialization in pharmaceutical medicine from the Faculty of Pharmaceutical Medicine in London. Dr. Quartel is board certified by the General Medical Council (GMC) in pharmaceutical medicine in the United Kingdom.

Rahsaan W. Thompson

Mr. Thompson brings more than 25 years of experience as a business leader and attorney in the biotech industry. Mr. Thompson, previously the Chief Legal Officer at Lyell Immunopharma, a publicly traded and clinical-stage biotech corporation, has extensive experience handling corporate governance, clinical studies, intellectual property, licensing arrangements, and litigation, among other responsibilities. His knowledge of financing plans and partnerships as well as regulatory and compliance matters have led to his success throughout his career. Prior to his role at Lyell, he was the Executive Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer at Gritstone bio, a publicly traded, clinical-stage biotech company. He previously served as General Counsel at Opiant Pharmaceuticals and Actelion Pharmaceuticals. Earlier in his career, Mr. Thompson worked in General and Corporate Counsel roles at Quarles & Brady, Abraxis Bioscience, McKesson Corporation and Assistant District Attorney in the Philadelphia District Attorney’s Office. Mr. Thompson serves on the Board of Trustees for the Oakland Museum of California and formerly the American Kidney Fund. He received his J.D. from Hofstra University School of Law and his B.Sc. from Southern Methodist University. He has Bar Admissions in the States of Illinois, California, and Pennsylvania.

Alison Peters

Ms. Peters brings more than 20 years of experience in human capital management at biopharmaceutical and medtech companies. Ms. Peters was previously the Chief People Officer and Head of Corporate Communications at Scipher Medicine, a mid-sized precision medicine company, where she played a key role in shaping a culture of high performance through various talent management initiatives. Prior to that, she was the Human Capital Practice Lead at Dominis Group, a human capital and finance consulting firm, where she provided executive coaching on culture, performance, and change management. She previously served as Senior Director of Talent Management at Serica Technologies and VP of Human Resources at Quantia MD, leading HR services and ensuring talent acquisition and retention at each company. Earlier in her career, Ms. Peters worked in Talent Acquisitions and HR for PCI Corporation, Etex Corporation, Akamai Technologies, GTE Internetworking, and Fidelity Investments.

Tanya Hayden

Ms. Hayden was previously the Chief Operating Officer of Acer Therapeutics, where she was primarily responsible for supporting operational and commercial growth and effectiveness, as well as establishing, improving, and scaling the company’s executional operations. Zevra Therapeutics acquired Acer Therapeutics in November of 2023, after which Ms. Hayden transitioned to the role of Senior Vice President, Chief of Staff.

Prior to joining Acer, Ms. Hayden spent 20 years at Lonza (formerly Bend Research/Capsugel) and held various roles, with increasing responsibilities across business unit planning and strategic projects, operational excellence, clinical and commercial contract manufacturing, and program management.

Throughout her career, Ms. Hayden has had the opportunity to lead internal cross-functional teams to introduce new capabilities and improve performance, as well as collaborate with external partners to advance new products to the market.

Ms. Hayden received her B.S. in chemistry from Gonzaga University.

Gerald Orehostky

Since 2020, Mr. Orehostky has held a variety of positions at the company including Sr. Director of Regulatory Affairs and Senior Vice President, Regulatory Affairs and Quality.

Mr. Orehostky oversees the Regulatory Affairs and Quality departments, supporting the development and commercialization of Zevra’s products. His responsibilities include oversight of operations, managing organizational growth, program planning and establishment of regulatory strategy required to support Zevra’s pipeline.

Over the past 37 years, prior to joining Zevra, he has served in various roles in regulatory affairs and quality functions. His experience includes the successful development and commercialization of drug, biologic, and combination products in multiple areas, including rare disease.

Mr. Orehostky received undergraduate degrees in biology and forensic sciences, a B.A. in Natural Science and Mathematics from Thomas Edison University, completed graduate studies in business administration, and obtained a quality engineering certification.

Christopher M. Lauderback, Ph.D.

Dr. Lauderback has served as Zevra Therapeutics (then KemPharm, Inc.) vice president, manufacturing since March 2016, having previously held the position of vice president, commercial operations since September 2012.

Prior to joining Zevra, Dr. Lauderback was the senior manager of CMC scientific affairs at Sigma-Tau Pharmaceuticals, Inc., a specialty pharmaceutical company, from June 2009 to September 2012. From 2008 to 2009, Dr. Lauderback worked as the director of product development at AirBase Therapeutics, LLC.

Dr. Lauderback started his career at New River Pharmaceuticals, where he served as a senior scientist from 2001 to 2006 and as associate director, CMC development from 2006 to 2007.

Dr. Lauderback received his doctorate from the University of Kentucky and his Bachelor of Science from Emory and Henry College.

Timothy Sangiovanni, CPA

Mr. Sangiovanni has served as Zevra Therapeutics (then KemPharm, Inc.) vice president, corporate controller since February 2017, having previously held the position of director, financial reporting since August 2015.

Prior to joining Zevra, Mr. Sangiovanni was the internal audit manager at Tupperware Brands Corporation, a leading publicly held marketer of home and personal care products, audit manager at KPMG LLP, a global network of professional firms providing audit, tax and advisory services, and billing analyst at Switch and Data Facilities Company, Inc. (today, Equinix, Inc.), a leading publicly held provider of global colocation data center services.

Mr. Sangiovanni is a Certified Public Accountant in the State of Florida and earned his Bachelor of Arts in accounting from the University of South Florida.